Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL465908 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL9625167 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL4933917 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL992285 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL1832445 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL292514 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL3199266 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL4784041 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL2031974 | 1.00 | ALDH1A1 (0.57) | ALDH1A1TSHRHSD17B10TDP1 | |
| Methylene Chloride SCHEMBL948 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024051784-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海璎黎药业有限公司 | 2024-03-14 | — | — | WO | disclosed |
| US-20030199560-A1 | Bisaryl compound and medicament for cancer treatment comprising the same | KYOWA HAKKO KOGYO CO., LTD. | 2003-10-23 | — | — | US | disclosed |
| EP-0990439-A1 | BISARYL COMPOUNDS AND CANCER REMEDIES CONTAINING THE SAME | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199560-A1 | Bisaryl compound and medicament for cancer treatment comprising the same | AR, NR5A1, SRD5A1 | ALDH1A1 597/4885TSHR 749/4885HSD17B10 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.